Managed care organizations (MCOs) are developing population-based approaches to illnesses with large numbers of patients, wide variations in care and outcomes, and high costs.
This is the first survey that evaluates current prostate cancer approaches by MCOs.
Case studies and a survey of corporate medical directors at large MCOs were conducted.
Two approaches, broadly based on disease management strategies for men with prostate cancer, have been implemented in managed care settings on the West Coast.
While both have provided comprehensive approaches to the disease, assessment of improvement in outcomes will require longer follow-up.
A survey of corporate medical directors of MCOs indicates that population-based disease approaches nationwide for malignant prostate disease lag behind more well-developed efforts for nonmalignant illnesses such as diabetes and asthma.
Prostate cancer may be a feasible area for development and evaluation of population-based approaches.
MCOs have the potential to improve clinical care and outcomes for large numbers of men with prostate cancer.
While limitations exist related to specific managed care considerations of data needs and lack of medical and surgical consensus on disease management, programs based on shared decision making have the potential to improve patient care and outcomes.
Mots-clés Pascal : Tumeur maligne, Prostate, Mâle, Homme, Etats Unis, Amérique du Nord, Amérique, Dépistage, Rapport coût bénéfice, Impact socioéconomique, Aide décision, Traitement, Qualité vie, Organisme contrôle, Appareil génital mâle pathologie, Appareil urinaire pathologie, Prostate pathologie
Mots-clés Pascal anglais : Malignant tumor, Prostate, Male, Human, United States, North America, America, Medical screening, Cost benefit ratio, Socioeconomical impact, Decision aid, Treatment, Quality of life, Supervisory institution, Male genital diseases, Urinary system disease, Prostate disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0392031
Code Inist : 002B14D02. Création : 12/09/1997.